Conflict of interest

Khandpur, Sujay; Pahwa, Pooja

doi:10.4103/0378-6323.51238

Cited by 4 publications

(5 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reverse is also true where experts in other speciality have studied a particular dermatosis without acknowledging the contribution of a dermatologist. [8] …”

Section: Always Disclose Conflict Of Interest and Source Of Funding mentioning

confidence: 97%

Why your manuscript was rejected and how to prevent it?

Dogra¹

2011

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

The journal issue has a unique new feature for reaching to the journal's website without typing a single letter. Each article on its first page has a "Quick Response Code". Using any mobile or other hand-held device with camera and GPRS/other internet source, one can reach to the full text of that particular article on the journal's website. Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal. It will automatically take you to the HTML full text of that article. One can also use a desktop or laptop with web camera for similar functionality. See

show abstract

“…The reverse is also true where experts in other speciality have studied a particular dermatosis without acknowledging the contribution of a dermatologist. [8] …”

Section: Always Disclose Conflict Of Interest and Source Of Funding mentioning

confidence: 97%

Why your manuscript was rejected and how to prevent it?

Dogra¹

2011

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy has been used with uneven results [8–12]. Some antiangiogenic drugs, such as bevacizumab and ranibizumab, have been used [13–15], but they do not provide long-term cessation of tumours’ growth [16, 17].…”

Section: Introductionmentioning

confidence: 99%

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

Albiñana

Escribano

Soler

et al. 2017

Orphanet J Rare Dis

View full text Add to dashboard Cite

BackgroundVon Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is characterized by the growth of different types of tumours. Haemangioblastomas in the central nervous system (CNS) and retina, renal carcinoma and pheochromocytomas are the most common tumours. The absence of treatment for VHL leads to the need of repeated surgeries as the only option for these patients. Targeting VHL-derived tumours with drugs with reduced side effects is urgent to avoid repeated CNS surgeries. Recent reports have demonstrated that propranolol, a β-blocker used for the treatment of hypertension and other cardiac and neurological diseases, is the best option for infantile hemangioma (IH). Propranolol could be an efficient treatment to control haemangioblastoma growth in VHL disease given its antiangiogenic effects that were recently demonstrated by us. The main objective of the present study was the assessment of the efficacy and safety of propranolol on retinal haemangioblastoma in von Hippel-Lindau disease (VHL).Methods7 VHL patients, from different regions of Spain, affected from juxtapapillary or peripheral haemangioblastomas were administered 120 mg propranolol daily. Patients were evaluated every 3 months for 12 months, at Virgen de la Salud Hospital (Toledo). The patients had juxtapapillary or peripheral haemangioblastomas but had refused standard treatments.ResultsPropranolol was initiated with a progressive increase up to a final dose of 120 mg daily. All tumours remained stable, and no new tumours appeared. The reabsorption of retinal exudation was noted in the two patients having exudates. No adverse effects were recorded. VEGF and miRNA 210 levels were monitored in the plasma of patients as possible biomarkers of VHL. These levels decreased in all cases from the first month of treatment.ConclusionsAlthough more studies are necessary, the results of this work suggest that propranolol is a drug to be considered in the treatment of VHL patients with retinal haemangioblastomas. VEGF and miRNA 210 could be used as biomarkers of the VHL disease activity.Trial registrationThe study has a clinical trial design and was registered at EU Clinical Trials Register and Spanish Clinical Studies Registry, EudraCT Number: 2014–003671-30. Registered 2 September 2014.

show abstract

“…Also whenever there is a question of human life, trials should be conducted and governed by moral and ethical principles. There are evidences given by Heffner, Milbrandt, and Venkataraman (2007), Lexchin (2013), Montaner, O’Shaughnessy, and Schechter (2001), Rothwell (2006) and Srinivasan and Nikarge (2009) which suggest that pharmaceutical industries often violate ethical guidelines with the use of some means in all stages of clinical trial. The problem with the ethical guidelines in India is that there is no penalty or punishment when they are violated.…”

Section: Resultsmentioning

confidence: 99%

“…However, if there does exist some sort of financial affiliation or conflict of interests between the investigator and an industry, it should be declared while presenting the results of the trial. In order to avoid malpractices from the financial bond between the investigators and sponsors, Khandpur and Pahwa (2009) and Clifford et al (2002)Dadhich (2012) suggest the procedure of registration should be completed well before the publication. In addition, Bodenheimer (2009) suggests more independence should be given to the investigators to carry out the trials without any intervention from the sponsors.…”

Section: Resultsmentioning

confidence: 99%

The Impact of Source of Funding on the Outcome of Clinical Trials in India

Ruqsana

2018

Arthaniti: Journal of Economic Theory and Practice

View full text Add to dashboard Cite

In recent times, there has been a surge of clinical trials in India. These trials are funded by different agents such as pharmaceutical industries, hospitals, research institutions, etc. Categorising the sponsors as pharmaceutical and non-pharmaceutical, this article tries to address the question whether the source of funding of the trials affects its outcome favourably. The study is carried out with 255 trials registered in Clinical Trials Registry-India from the year 2007 to 2009. Multivariate logistic regression analysis suggests that the trials conducted by pharmaceutical industries have significantly (at 10% level of significance) higher probability of success as compared to those sponsored by non-pharmaceutical industries. The possible reasons for this association are that trials conducted by pharmaceutical industries are in higher phase of study, use placebo as a control, are conducted in multiple centres and consist of large sample size. JEL: I11, C51

show abstract

Conflict of interest

Cited by 4 publications

References 12 publications

Why your manuscript was rejected and how to prevent it?

Why your manuscript was rejected and how to prevent it?

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

The Impact of Source of Funding on the Outcome of Clinical Trials in India

Contact Info

Product

Resources

About